Neil Mehta

9.9k total citations · 4 hit papers
152 papers, 5.3k citations indexed

About

Neil Mehta is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Neil Mehta has authored 152 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Hepatology, 75 papers in Epidemiology and 55 papers in Surgery. Recurrent topics in Neil Mehta's work include Hepatocellular Carcinoma Treatment and Prognosis (92 papers), Liver Disease Diagnosis and Treatment (70 papers) and Liver Disease and Transplantation (53 papers). Neil Mehta is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (92 papers), Liver Disease Diagnosis and Treatment (70 papers) and Liver Disease and Transplantation (53 papers). Neil Mehta collaborates with scholars based in United States, Canada and United Kingdom. Neil Mehta's co-authors include Francis Y. Yao, John P. Roberts, Jennifer L. Dodge, Heather Williams, Gonzalo Sapisochín, Ryutaro Hirose, Bilal Hameed, Julie K. Heimbach, Arno J. Mundt and Nicholas Fidelman and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Neil Mehta

145 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

2023 740 citations Amit G. Singal, Neil Mehta et al. Hepatology profile →
Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria

2015 325 citations Francis Y. Yao, Neil Mehta et al. Hepatology profile →
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma

2022 97 citations Parissa Tabrizian, Matthew L. Holzner et al. profile →
AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation

2023 75 citations Amy M. Shui, Francis Y. Yao et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil Mehta United States	35	3.4k	2.2k	1.7k	839	671	152	5.3k
Dietrich von Schweinitz Germany	46	1.2k 0.4×	724 0.3×	1.8k 1.0×	1.5k 1.8×	754 1.1×	189	6.8k
Monica Miozzo Italy	40	349 0.1×	454 0.2×	466 0.3×	883 1.1×	853 1.3×	158	5.0k
Tatyana V. Masyuk United States	33	697 0.2×	426 0.2×	1.4k 0.8×	293 0.3×	267 0.4×	58	4.0k
Robin D. Kim United States	25	763 0.2×	252 0.1×	1.0k 0.6×	491 0.6×	432 0.6×	62	2.3k
Penelope Brock United Kingdom	34	1.3k 0.4×	692 0.3×	1.1k 0.6×	1.6k 2.0×	782 1.2×	93	4.9k
Shin Fujita Japan	39	281 0.1×	320 0.1×	2.2k 1.3×	2.9k 3.5×	812 1.2×	117	4.3k
William H. Fleming United States	35	225 0.1×	540 0.3×	817 0.5×	739 0.9×	680 1.0×	107	4.0k
Otto Dietze Austria	28	217 0.1×	378 0.2×	439 0.3×	979 1.2×	471 0.7×	125	2.8k
Steven Gallinger Canada	24	249 0.1×	220 0.1×	711 0.4×	874 1.0×	587 0.9×	68	2.8k
Mary Ella Pierpont United States	36	142 0.0×	1.6k 0.7×	1.2k 0.7×	332 0.4×	834 1.2×	98	6.0k

Countries citing papers authored by Neil Mehta

Since Specialization

Citations

This map shows the geographic impact of Neil Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Mehta more than expected).

Fields of papers citing papers by Neil Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Mehta. The network helps show where Neil Mehta may publish in the future.

Co-authorship network of co-authors of Neil Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Mehta. A scholar is included among the top collaborators of Neil Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Mehta. Neil Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mehta, Neil, et al.. (2025). The Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma. Current Hepatology Reports. 24(1). 3 indexed citations

Zhou, Kali, Laura Thompson, Jennifer L. Dodge, et al.. (2025). Longer travel and traffic are associated with adult liver transplant waitlist mortality in the United States. American Journal of Transplantation. 25(7). 1515–1525.

Tabrizian, Parissa, Julio R. Gutiérrez, Maarouf Hoteit, et al.. (2025). Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study. Hepatology. 82(3). 612–625. 3 indexed citations

Amara, Dominic, Fady M. Kaldas, Douglas G. Farmer, et al.. (2025). Impact of Normothermic Machine Perfusion on Access to Liver Transplantation in Patients With Primary Hepatic Malignancies. Clinical Transplantation. 39(8). e70254–e70254.

Saxena, Varun, et al.. (2024). Survival Outcomes Among Patients With Hepatocellular Carcinoma in a Large Integrated US Health System. JAMA Network Open. 7(9). e2435066–e2435066. 16 indexed citations

Martin, Sean P., Neil Mehta, & Juliet Emamaullee. (2024). Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities. Liver Transplantation. 30(7). 742–752. 3 indexed citations

Zhou, Kali, Sachin Shah, Laura Thompson, & Neil Mehta. (2024). Bridging the rural-urban gap in access to liver transplantation. Clinical Liver Disease. 23(1). e0160–e0160. 3 indexed citations

Li, Michael, Sherrie Bhoori, Neil Mehta, & Vincenzo Mazzaferro. (2024). Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation. Journal of Hepatology. 81(4). 743–755. 21 indexed citations

Zhou, Kali, Lauren Nguyen, Parissa Tabrizian, & Neil Mehta. (2024). Sociodemographic disparities in downstaging to liver transplant for hepatocellular carcinoma. Liver Transplantation. 31(4). 556–559.

10.

Mehta, Neil, Robin Katie Kelley, & Francis Y. Yao. (2023). Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies. Hepatology. 80(1). 238–253. 9 indexed citations

11.

Mehta, Neil, et al.. (2023). Patient survey augments detection of harmful alcohol relapse after liver transplant for alcohol-associated cirrhosis. Hepatology Communications. 7(5). 1 indexed citations

12.

Tabrizian, Parissa, Maarouf Hoteit, Catherine Frenette, et al.. (2023). Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the “all-comers” protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium. American Journal of Transplantation. 23(11). 1771–1780. 9 indexed citations

13.

Yao, Francis Y., Joshua D. Grab, Hillary J. Braun, et al.. (2022). National experience with living donor liver transplantation for hepatocellular carcinoma. Liver Transplantation. 28(7). 1144–1157. 11 indexed citations

14.

Huang, Annsa C., Jennifer L. Dodge, Francis Y. Yao, & Neil Mehta. (2022). National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clinical Gastroenterology and Hepatology. 21(6). 1581–1589. 14 indexed citations

15.

Mehta, Neil, Catherine Frenette, Parissa Tabrizian, et al.. (2021). Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 161(5). 1502–1512. 80 indexed citations

16.

Mehta, Neil. (2021). Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management. Clinical Liver Disease. 17(5). 332–336. 23 indexed citations

17.

Mehta, Neil, Neehar D. Parikh, Robin Katie Kelley, Bilal Hameed, & Amit G. Singal. (2020). Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clinical Gastroenterology and Hepatology. 19(8). 1520–1530. 21 indexed citations

18.

Mehta, Neil, Jennifer L. Dodge, John P. Roberts, Ryutaro Hirose, & Francis Y. Yao. (2018). Alpha‐Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 69(3). 1193–1205. 70 indexed citations

19.

Mehta, Neil, Jennifer L. Dodge, John P. Roberts, Ryutaro Hirose, & Francis Y. Yao. (2017). Misdiagnosis of hepatocellular carcinoma in patients receiving no local‐regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clinical Transplantation. 31(11). 8 indexed citations

20.

Mehta, Neil, Jennifer Guy, Catherine Frenette, et al.. (2017). Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clinical Gastroenterology and Hepatology. 16(6). 955–964. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact